Regulation of c-Fos and c-Jun gene expression by phospholipase C activity in adult cardiomyocytes

Molecular and Cellular Biochemistry

Volumn 327, Issue 1-2, 2009, Pages 229-239

  Singal, Tushi ^a   Dhalla, Naranjan S ^a   Tappia, Paramjit S ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b I H Asper Clinical Research Institute   (Canada)

Author keywords

Adult cardiomyocytes; Extracellular signal regulated kinase; Gene expression; Phospholipase C; Protein kinase C; Signal transduction; Transcription factors

Indexed keywords

ANIMALS; GENE EXPRESSION REGULATION; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCYTES, CARDIAC; NOREPINEPHRINE; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TYPE C PHOSPHOLIPASES;

RATTUS;

EID: 67349140505     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-009-0061-1     Document Type: Article

References (48)

1. Tappia PS (2007) Phospholipid-mediated signaling systems as novel targets for treatment of heart disease. Can J Physiol Pharmacol 85:25-41. doi: 10.1139/Y06-098
2. Tappia PS, Singal T, Dent MR, Asemu G, Mangat R, Dhalla NS (2006) Phospholipid-mediated signaling in diseased myocardium. Future Lipidol 1:701-717. doi: 10.2217/17460875.1.6.701
3. Hannan RD, West AK (1991) Adrenergic agents, but not triiodo-L -thyronine induce c-fos and c-myc expression in the rat heart. Basic Res Cardiol 86:154-164. doi: 10.1007/BF02190548
4. Saadane N, Alpert L, Chalifour LE (1999) Expression of immediate early genes, GATA-4 and Nkx-2.5 in adrenergic-induced cardiac hypertrophy and during regression in adult mice. Br J Pharmacol 127:1165-1176
5. 1-adrenoceptor subtype activation increases proto-oncogene mRNA levels. Eur J Pharmacol 342:311-317. doi: 10.1016/S0014-2999(97)01465-9
6. Hannan RD, Stennard FA, West AK (1993) Expression of c-fos and related genes in the rat heart in response to norepinephrine. J Mol Cell Cardiol 25:1137-1148. doi: 10.1006/jmcc.1993.1127
7. Schunkert H, Jahn L, Izumo S, Apstein CS, Lorell BH (1991) Localization and regulation of c-fos and c-jun protooncogene induction by systolic wall stress in normal and hypertrophied rat hearts. Proc Natl Acad Sci USA 88:11480-11484. doi: 10.1073/pnas.88.24.11480
8. Omura T, Yoshiyama M, Yoshida K, Nakamura Y, Kim S, Iwao H, Takeuchi K, Yoshikawa J (2002) Dominant negative mutant of c-Jun inhibits cardiomyocyte hypertrophy induced by endothelin 1 and phenylephrine. Hypertension 39:81-86. doi: 10.1161/hy0102.100783
9. Kovacic-Milivojevic B, Wong VS, Gardner DG (1996) Selective regulation of the atrial natriuretic peptide gene by individual components of the activator protein-1 complex. Endocrinology 137:1108-1117. doi: 10.1210/ en.137.3.1108
10. Schnabel P, Mies F, Nohr T, Geisler M, Böhm M (2000) Differential regulation of phospholipase C-β isozymes in cardiomyocyte hypertrophy. Biochem Biophys Res Commun 275:1-6. doi: 10.1006/ bbrc.2000.3255
11. Singal T, Dhalla NS, Tappia PS (2004) Phospholipase C may be involved in norepinephrine-induced cardiac hypertrophy. Biochem Biophys Res Commun 320:1015-1019. doi: 10.1016/j.bbrc.2004.06.052
12. Wu B, Wang TH, Zhu XN, Pan JY (1999) ET-1 induces the expression of prooncogene c-fos in cultured neonatal rat myocardial cells. Sheng Li Xue Bao 51:19-24
13. Yang HY, Liu JC, Chen YL, Chen CH, Lin H, Lin JW, Chiu WT, Chen JJ, Cheng TH (2005) Inhibitory effect of triliolein on endothelin-1-induced c-fos gene expression in cultured neonatal rat cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 372:160-167. doi: 10.1007/s00210-005-0003-8
14. Singal T, Dhalla NS, Tappia PS (2006) Norepinephrine-induced changes in gene expression of phospholipase C in cardiomyocytes. J Mol Cell Cardiol 41:126-137. doi: 10.1016/j.yjmcc.2006.03.004
15. Winer J, Jung CK, Shackel I, Williams PM (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270:41-49. doi: 10.1006/abio.1999.4085
16. Dent MR, Dhalla NS, Tappia PS (2004) Phospholipase C gene expression, protein content, and activities in cardiac hypertrophy and heart failure due to volume overload. Am J Physiol Heart Circ Physiol 287:H719-H727. doi: 10.1152/ajpheart.01107.2003
17. Ziegelhoffer A, Tappia PS, Mesaeli N, Sahi N, Dhalla NS, Panagia V (2001) Low level of sarcolemmal phosphatidylinositol 4,5-bisphosphate in cardiomyopathic hamster (UM-X7.1) heart. Cardiovasc Res 49:118-126
18. Suh P-G, Ryu SO, Choi WC, Lee KY, Rhee SG (1988) Monoclonal antibodies to three phospholipase C isozymes from bovine brain. J Biol Chem 263:14497-14504
19. 1 on serine and tyrosine residues in a human T-cell line. Proc Natl Acad Sci USA 88:5433-5456. doi: 10.1073/pnas.88.12.5433
20. Strauer BE, Bayer T, Brecht HM, Motz W (1985) The influence of sympathetic nervous activity on regression of cardiac hypertrophy. J Hypertens 3:S39-S44. doi: 10.1097/00004872-198502000-00007
21. Clerk A, Kemp TJ, Harrison JG, Mullen AJ, Barton PJR, Sugden PH (2002) Up-regulation of c-jun mRNA in cardiac myocytes requires the extracellular signal-regulated kinase cascade, but c-Jun N-terminal kinases are required for efficient up-regulation of c-Jun protein. Biochem J 368:101-110. doi: 10.1042/BJ20021083
22. Sanna B, Bueno OF, Dai YS, Wilkins BJ, Molkentin JD (2005) Up-regulation of c-jun mRNA in cardiac myocytes requires the extracellular signal-regulated kinase cascade, but c-Jun N-terminal kinases are required for efficient up-regulation of c-Jun protein. Mol Cell Biol 25:865-878. doi: 10.1128/MCB.25.3.865-878.2005
23. Rhee SG (2001) Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 70:281-312. doi: 10.1146/annurev.biochem.70.1.281
24. 1B-adrenoceptor interacts with multiple sites of transglutaminase II: Characteristics of the interaction in binding and activation. Biochemistry 38:2224-2232. doi: 10.1021/bi9823176
25. h (transglutaminase II) by compartment: GTPase and transglutaminase activities. Biochem Biophys Res Commun 284:496-500. doi: 10.1006/bbrc.2001.4997
26. Hefti MA, Harder BA, Eppenberger HM, Schaub MC (1997) Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol 29:2873-2892. doi: 10.1006/jmcc.1997.0523
27. Tappia PS, Padua RR, Panagia V, Kardami E (1999) Fibroblast growth factor-2 stimulates phospholipase Cβ in adult cardiomyocytes. Biochem Cell Biol 77:569-575. doi: 10.1139/bcb-77-6-569
28. 2+ inflow. Biochem Pharmacol 49:1373-1379. doi: 10.1016/ 0006-2952(95)00050-A
29. 2+ release and directly activates ion channels in mouse pancreatic acinar cells. Biochem J 324:645-651
30. Muto Y, Nagao Y, Urishidani T (1997) The putative phospholipase C inhibitor U73122 and its negative control, U73343, elicit unexpected effects on the rabbit parietal cell. Pharmacol Exp Ther 282:1379-1388
31. 1 -mediated response. J Biol Chem 265:3809-13817
32. Taimor G, Schlüter KD, Best P, Helmig S, Piper HM (2004) Transcription activator protein 1 mediates α- but not β-adrenergic hypertrophic growth responses in adult cardiomyocytes. Am J Physiol Heart Circ Physiol 286:H2369-H2375. doi: 10.1152/ ajpheart.00741.2003
33. Sabri A, Steinberg SF (2003) Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem 251:97-101. doi: 10.1023/A:1025490017780
34. 1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 33:779-787. doi: 10.1006/jmcc.2001.1348
35. Curran T, Franza BR Jr (1988) Fos and Jun: The AP-1 connection. Cell 55:395-397. doi: 10.1016/0092-8674(88)90024-4
36. Kaminska B, Pyrzynska B, Ciechomska I, Wisniewska M (2000) Modulation of the composition of AP-1 complex and its impact on transcriptional activity. Acta Neurobiol Exp (Wars) 60:395-402
37. Giles TD, Sander GE, Thomas MG, Quiroz AC (1986) α-adrenergic mechanisms in the pathophysiology of left ventricular heart failure-An analysis of their role in systolic and diastolic dysfunction. J Mol Cell Cardiol 18:33-43. doi: 10.1016/S0022-2828(86)80459-X
38. Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B (2006) Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 113:1588-1596. doi: 10.1161/ CIRCULATIONAHA.105.574822
39. Motz W, Klepzig M, Strauer BE (1987) Regression of cardiac hypertrophy: experimental and clinical results. J Cardiovasc Pharmacol 10:S148-S152
40. Prasad K, O'Neil CL, Bharadwaj B (1984) Effect of prolonged prazosin treatment on hemodynamic and biochemical changes in the dog heart due to chronic pressure overload. Jpn Heart J 25:461-476
41. Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K (2007) Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: The LIFE Study. Circulation 116:700-705. doi: 10.1161/CIRCULATIONAHA.106.666594
42. Rosenzweig A, Halazonetis TD, Seidman JG, Seidman CE (1991) Proximal regulatory domains of rat atrial natriuretic factor gene. Circulation 84:1256-1265
43. Dent MR, Singal T, Tappia PS, Gupta SK, Dhalla NS (2007) Involvement of renin-angiotensin system in the pathogenesis of cardiovascular disease. In: Ray A, Gulati K (eds) Current trends in pharmacology. IK International Publishing House Pvt. Ltd, New Delhi, pp 137-160
44. Aoki H, Richmond M, Izumo S, Sadoshima J (2000) Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem J 347:275-284. doi: 10.1042/ 0264-6021:3470275
45. 3 and extracellular signal-regulated kinase 1/2 via angiotensin II type 1 receptor. Chin Med J 117:88-934
46. Lijnen P, Petrov V (1999) Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. J Mol Cell Cardiol 31:949-970. doi: 10.1006/jmcc.1999.0934
47. Moen MD, Wagstaff AJ (2005) Losartan: A review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs 65:2657-2674. doi: 10.2165/00003495-200565180-00012
48. Dent MR, Aroutiounova N, Dhalla NS, Tappia PS (2006) Losartan attenuates phospholipase C isozyme gene expression in hypertrophied hearts due to volume overload. J Cell Mol Med 10:470-479. doi: 10.1111/ j.1582-4934.2006.tb00412.x